Avoro Capital Advisors LLC: CENTESSA PHARMACEUTICALS PLC (CNTA): Quarterly 13F Position History
As of Q1 2026, Avoro Capital Advisors LLC reported 11,430,455 shares of CENTESSA PHARMACEUTICALS PLC (CNTA), worth $454.0M and representing 4.5% of its 13F equity book. Quarter-over-quarter share count change: 3,125,100 (-21.5%) . The position first appeared in Q2 2021 and has been disclosed across 20 13F-HR filings in Pactolio's tracked window.
- 11,430,455Shares Held (Latest Filing)
- $454.0MReported Market Value (Latest Filing)
- 4.5%Portfolio Weight (% of 13F Equity Book)
- 3,125,100Quarter-over-Quarter Share Change
- +$90.0MQuarter-over-Quarter Value Change
- 14,555,555Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 20 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 11,430,455 | 3,125,100 | -21.5% | $454.0M | 4.5% | $39.7 |
| Q4 2025 | 14,555,555 | +3,747,475 | +34.7% | $364.0M | 3.6% | $25.0 |
| Q3 2025 | 10,808,080 | +5,808,080 | +116.2% | $262.1M | 3.4% | $24.3 |
| Q2 2025 | 5,000,000 | +950,000 | +23.5% | $65.7M | 1.2% | $13.1 |
| Q1 2025 | 4,050,000 | +4,050,000 | — | $58.2M | 0.9% | $14.4 |
| Q4 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2021 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2021 | 0 | 500,000 | -100.0% | $0 | 0.0% | — |
| Q2 2021 | 500,000 | — | — | $11.1M | 0.2% | $22.2 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Avoro Capital Advisors LLC first disclose a CNTA position in 13F-HR filings?
Avoro Capital Advisors LLC first reported CENTESSA PHARMACEUTICALS PLC (CNTA) on its 13F-HR filing for the period ending 2021-06-30 (Q2 2021). The position has appeared on 20 reported quarters within Pactolio's tracked window.
What was Avoro Capital Advisors LLC's most recent quarter-over-quarter share-count change in CNTA?
Between Q4 2025 and Q1 2026, Avoro Capital Advisors LLC reduced its CNTA position by 3,125,100 shares (-21.5%), leaving 11,430,455 shares at a market value of $454.0M.
Does the implied price-per-share represent Avoro Capital Advisors LLC's cost basis in CNTA?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.